



DR. RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES
VIBHUTI KHAND, GOMTI NAGAR, LUCKNOW-10(U.P)
Phone No : - 0522-4918502, 4918510

Ref No: ~~1187~~ HRF/PAC/2026

Dated: 24 Feb. 2026

Notice

Sub:- Procurement of following items on proprietary/ single quotation basis for different department

The Dr. RMLIMS, Lucknow intend to procure following item (s) manufactured as per mentioned against item name for **Niraparib Tablets 100mg** on proprietary/ single quotation basis from their authorized dealer/ seller as per enclosed Technical Specifications.


Sl no	Product details	Principle Company (Manufacturer)	Subsidiary Company (Marketing)	Authorised Seller/ Company/Dealer
1	Niraparib Tablets 100mg (Brand Name:- Zejula)	M/s Catalent Greenville, Inc.,1240 Sugg Parkway, Greenville, North Carolina(NC), US	N.A	M/s GSK Pharma India Private Limited, Battery House, Bhulabhai Desai Road, Mumbai-400026

The Proprietary Certificate for above items (s) submitted by principle company or their authorized seller/ Company/ Dealer is attached. The above documents are being uploaded for open information to all manufacturer/ supplier to submit comments / objections/ representation on the chairmen. (HRF), Dr RMLIMS, Lucknow on email id hrtendercell@gmail.com, from the date mentioned above, falling which it will be presumed that no other supplier is having any comment to offer and the case will be decided on merits. The comments/objection/representation to be submitted on the following:-

- (i) Weather the above medicine/surgical items is manufactured by any other manufacture other than as per mentioned principle company or their Authorized seller/company/Dealer.
- (ii) Fulfill all the parameter(s) as per technical specifications.

Encl: - Related documents enclosed.

- (1) HRF Requisition form
- (2) PAC Certification of company letter.
- (3) Authorization from company letter.


Chairman (HRF)
Dr. RMLIMS, Lucknow

HRF Requisition Form

Request for new items/upgraded version (Drugs, Consumables & Disinfectants)

('X' if is not applicable)

1. Name of item (generic name only, no brand name) Niraparib 100 mg
Tablets

Please note that if another brand of the same item is already available in HRF, the request will not be entertained for another brand.

2. Quantity needed (Per month) 112 Tab

3. Probable Source (I)

(II)

(III)

(If only one source please sign. The P-3 Form on back page)

4. Similar item available In HRF inventory? -Yes/No

5. If yes then, why this item?

6. Do you want this item to be made available on regular basis -Yes/No

7. If yes, then what will be the monthly consumption of this item?

8. Is same item in single unit be used on many patients? If yes then specify the Number of times/Number of patients, the unit will be used.....

9. Will it be a part of any procedure (Dossier, please specify the name of procedure) N/A

10. If it is an upgraded version of an existing item in HRF inventory, do you want old version to continue? - N/A -Yes/No

11. Justification for new requisition Niraparib has superior clinical advantages regardless of only mutation in adult patient of ovarian cancer as convenient monotherapy (PRIME TRIAL)

Dr. Saksham Singh
(Sign. of Consultant)
Assistant Professor (Medical Oncology)
MD, DM, FRCR, FRCR (Oncology), FRCR (BMT)

Dr. Rohini Khurana Sethi
(Signature of Head of Department)
MD, MAMS, FRCR
HOD, Medical Oncology
Dr. R.M.L.I.M.S., Lucknow

Please note that new item will be processed for short-term rate contract- this may take about 1-2 months time.

new B3
R
18/12/26
KD HRF
18/12/26

AD CHRM
18/12/26

Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow

PROPRIETARY ARTICLE CERTIFICATE

It is certified that the items required should be purchased from M/s. *Galaxy Smith Kline Pharma (India) Pvt. Ltd.* Who are the sole manufacture/agents of the sole manufacturers M/s *Galaxo. Greenville, Inc., North Carolina, United States*

Similar items manufactured by other firm(s) shall not be suitable for our purpose for the following reasons: - *Niraparib has shown superior clinical advantage regardless of only mutation in adult patient of ovarian cancer as concurrent chemotherapy (PRIME TRADE)*

Jr. Ansham Singh
Assistant Professor (Medical Oncology)
M.D. (Oncology) MCh (Oncology) FRCR FRCR BMT
Signature of Indenter

Requisition No:

Department :

Dated :

Rohini Khurana Sethi
DR. ROHINI KHURANA SETHI
MD, MAMS, FRCR
Professor Radiation Oncology
Medical Oncology
Dr. P.M.L.M.S. Lucknow
Designation &
Sign of Head of
Department/ Section

N.B. The Indenter before recording the above certificate should satisfy himself that the article is genuinely of proprietary nature manufactured under patent laws.

PD 018165 IN-TH



GOVERNMENT OF INDIA
PATENT OFFICE

Tel No. (091)(011) 28081922 - 25
Fax No. 011 28081940,20



INTELLECTUAL PROPERTY BUILDING
Plot No. 32, Sector-14, Dwarka, New Delhi - 110 075 Web Site : www.ipindia.nic.in

PATENTS / DESIGNS / TRADE MARKS
GEOGRAPHICAL INDICATIONS

13920

Dated the: 22/12/2015

No. 270342

To
LAKSHMIKUMARAN &
SRIDHARAN B6/10,
Safdarjung Enclave New
Delhi 110029 India

BY REGISTERED A.D

REF :- Patent No.270342 (4674/DELNP/2009), Dated 17/07/2009(Ante-Dated :08/01/2008) Granted On Dated 14/12/2015

This is to state that a patent has been granted on the above-mentioned application and that the grant of the patent has been recorded in the Register of Patents on the 18/12/2015. The said patent is enclosed herewith.

The payment of renewal fee is required to be made at this office within three(3) months from the aforesaid date of recording according to the proviso in sub-section(4) of Section 142 of the Patents Act,1970, as Amended by the Patent(Amendment)Act,2005/ Patent Rule, 2003 as Amended by Patent(Amendment) Rules,2006.

The renewal fee schedule has been given at the back of the Letter of Patent

Encl: As above

(Hardev Karar)
Deputy Controller of Patents & Designs

Note: "Renewal fees have changed in accordance with the Patent Amendment Rules 2014; Kindly refer to the First Schedule (fees) of the Patent Amendment Rules 2014 available on the official website of Controller General of Patents Designs and Trade Marks www.ipindia.gov.in"

This is to state that a patent has been granted on the above-mentioned application and that the grant of the patent has been recorded in the Register of Patents on the 18/12/2015. The said patent is enclosed herewith.

The payment of renewal fee is required to be made at this office within three(3) months from the aforesaid date of recording according to the proviso in sub-section(4) of Section 142 of the Patents Act,1970, as Amended by the Patent(Amendment)Act,2005/ Patent Rule, 2003 as Amended by Patent(Amendment) Rules,2006.

The renewal fee schedule has been given at the back of the Letter of Patent

Encl: As above

(Hardev Karar)
Deputy Controller of Patents & Designs

Note: "Renewal fees have changed in accordance with the Patent Amendment Rules 2014; Kindly refer to the First Schedule (fees) of the Patent Amendment Rules 2014 available on the official website of Controller General of Patents Designs and Trade Marks www.ipindia.gov.in"

30/12/15
97305

Catalent

1240 Sugg Parkway
Greenville, NC 27834
catalent.com

+ 1 888 SOLUTION (76588466)

To Whom It May Concern

Proprietary Article Certificate for
Niraparib Tablets 100 mg [Brand name: Zejula]

M/s. Catalent Greenville, Inc., 1240 Sugg Parkway, Greenville, North Carolina (NC), United States - 27834, is the sole manufacturer and is responsible for the overall quality for the bulk product Niraparib Tablets 100mg [Brand name: Zejula].

Niraparib Tablets 100 mg [Brand name: Zejula] is a proprietary product of GSK group of companies.

GSK Pharma India Private Limited, India (Indian subsidiary of GSK group of companies) is the sole distributor Niraparib Tablets 100 mg [Brand name: Zejula] in India and is authorized to import and market the product and ensure supplies to all medical institutions/hospitals in India.

Authorized Signatory
(For para 1)

Chuck Walker

Electronically signed by: Chuck Walker
Reason: I approve this document.
Date: Feb 13, 2025 10:18 EST

Date: 13-Feb-2025

Name: Chuck Walker
Designation: Head of Quality
Catalent Greenville Inc.a
1240 Sugg Parkway
Greenville, NC 27834
USA

Authorized Signatory
(For para 2 and 3)

Sukanya Choudhury

Digitally signed by SUKANYA CHOUDHURY
Reason: I am signing this document as
authorized signatory for regulatory
submissions
Date: 2025-02-14 11:44:27+05:30

Date: 14-Feb-2025

Name: Sukanya Choudhury
Designation: Authorized Signatory
Regulatory Affairs, India